Institution
University of Colorado Boulder
Education•Boulder, Colorado, United States•
About: University of Colorado Boulder is a education organization based out in Boulder, Colorado, United States. It is known for research contribution in the topics: Population & Galaxy. The organization has 48794 authors who have published 115151 publications receiving 5387328 citations. The organization is also known as: CU Boulder & UCB.
Topics: Population, Galaxy, Context (language use), Poison control, Stars
Papers published on a yearly basis
Papers
More filters
••
University of Texas MD Anderson Cancer Center1, Duke University2, University of South Florida3, Northwestern University4, City of Hope National Medical Center5, Fox Chase Cancer Center6, University of California, San Diego7, Seattle Cancer Care Alliance8, Brigham and Women's Hospital9, Memorial Sloan Kettering Cancer Center10, Case Western Reserve University11, University of Utah12, University of Michigan13, Roswell Park Cancer Institute14, Mayo Clinic15, Yale Cancer Center16, Johns Hopkins University17, University of California, San Francisco18, University of Colorado Boulder19, Vanderbilt University20, Washington University in St. Louis21, University of Nebraska Medical Center22, Ohio State University23, Stanford University24, University of Tennessee Health Science Center25, Harvard University26
TL;DR: The recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease are discussed.
Abstract: Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Several advances have been made in the staging procedures, imaging techniques, and treatment approaches. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer provide an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. This manuscript discusses the recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease.
677 citations
••
Vardan Khachatryan1, Albert M. Sirunyan1, Armen Tumasyan1, Wolfgang Adam +2134 more•Institutions (142)
TL;DR: The couplings of the Higgs boson are probed for deviations in magnitude from the standard model predictions in multiple ways, including searches for invisible and undetected decays, and no significant deviations are found.
Abstract: Properties of the Higgs boson with mass near 125 GeV are measured in proton-proton collisions with the CMS experiment at the LHC. Comprehensive sets of production and decay measurements are combined. The decay channels include gamma gamma, ZZ, WW, tau tau, bb, and mu mu pairs. The data samples were collected in 2011 and 2012 and correspond to integrated luminosities of up to 5.1 inverse femtobarns at 7 TeV and up to 19.7 inverse femtobarns at 8 TeV. From the high-resolution gamma gamma and ZZ channels, the mass of the Higgs boson is determined to be 125.02 +0.26 -0.27 (stat) +0.14 -0.15 (syst) GeV. For this mass value, the event yields obtained in the different analyses tagging specific decay channels and production mechanisms are consistent with those expected for the standard model Higgs boson. The combined best-fit signal relative to the standard model expectation is 1.00 +/- 0.09 (stat) +0.08 -0.07 (theo) +/- 0.07 (syst) at the measured mass. The couplings of the Higgs boson are probed for deviations in magnitude from the standard model predictions in multiple ways, including searches for invisible and undetected decays. No significant deviations are found.
677 citations
••
University College London1, International Institute for Applied Systems Analysis2, United Nations University3, University of London4, World Bank5, University of Colorado Boulder6, Umeå University7, Tsinghua University8, World Health Organization9, University of Exeter10, University of Birmingham11, Royal Veterinary College12, University of Washington13, International Livestock Research Institute14, University of York15, Cayetano Heredia University16, University of Sussex17, University of Arkansas at Monticello18, University of Essex19, Baqiyatallah University of Medical Sciences20, Iran University of Medical Sciences21, Imperial College London22, University of Reading23, World Meteorological Organization24
TL;DR: The Lancet Countdown track progress on health and climate change and provides an independent assessment of the health effects of climate change, the implementation of the Paris Agreement, 1 and 3.
676 citations
••
TL;DR: Evidence for the involvement of IL‐1β and the clinical results of reducing IL‐ 1β activity in this broad spectrum of inflammatory diseases are the focus of this review.
Abstract: An expanding spectrum of acute and chronic non-infectious inflammatory diseases is uniquely responsive to IL-1β neutralization. IL-1β-mediated diseases are often called "auto-inflammatory" and the dominant finding is the release of the active form of IL-1β driven by endogenous molecules acting on the monocyte/macrophage. IL-1β activity is tightly controlled and requires the conversion of the primary transcript, the inactive IL-1β precursor, to the active cytokine by limited proteolysis. Limited proteolysis can take place extracellularly by serine proteases, released in particular by infiltrating neutrophils or intracellularly by the cysteine protease caspase-1. Therefore, blocking IL-1β resolves inflammation regardless of how the cytokine is released from the cell or how the precursor is cleaved. Endogenous stimulants such as oxidized fatty acids and lipoproteins, high glucose concentrations, uric acid crystals, activated complement, contents of necrotic cells, and cytokines, particularly IL-1 itself, induce the synthesis of the inactive IL-1β precursor, which awaits processing to the active form. Although bursts of IL-1β precipitate acute attacks of systemic or local inflammation, IL-1β also contributes to several chronic diseases. For example, ischemic injury, such as myocardial infarction or stroke, causes acute and extensive damage, and slowly progressive inflammatory processes take place in atherosclerosis, type 2 diabetes, osteoarthritis and smoldering myeloma. Evidence for the involvement of IL-1β and the clinical results of reducing IL-1β activity in this broad spectrum of inflammatory diseases are the focus of this review.
676 citations
••
TL;DR: In this article, the HWM90 thermospheric wind model has been revised in the lower thermosphere and extended into the mesosphere, stratosphere and lower atmosphere to provide a single analytic model for calculating zonal and meridional wind profiles representative of the climatological average for various geophysical conditions.
676 citations
Authors
Showing all 49233 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yi Chen | 217 | 4342 | 293080 |
Robert J. Lefkowitz | 214 | 860 | 147995 |
Rob Knight | 201 | 1061 | 253207 |
Charles A. Dinarello | 190 | 1058 | 139668 |
Jie Zhang | 178 | 4857 | 221720 |
David Haussler | 172 | 488 | 224960 |
Bradley Cox | 169 | 2150 | 156200 |
Gang Chen | 167 | 3372 | 149819 |
Rodney S. Ruoff | 164 | 666 | 194902 |
Menachem Elimelech | 157 | 547 | 95285 |
Jay Hauser | 155 | 2145 | 132683 |
Robert E. W. Hancock | 152 | 775 | 88481 |
Robert Plomin | 151 | 1104 | 88588 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Rajesh Kumar | 149 | 4439 | 140830 |